Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome, Partial Fetal Alcohol Syndrome, Alcohol Related Neurodevelopmental Disorder, Prenatal Alcohol Exposure
Conditions
Keywords
FASD, FAS, Alcohol, Prenatal Alcohol
Brief summary
The purpose of this study is to determine if choline bitartrate can be administered daily to children with prenatal alcohol exposure, ages 2.5 to 5, as a potential treatment for brain development and cognitive functioning.
Interventions
Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
Sponsors
Study design
Eligibility
Inclusion criteria
* Available parent or legal guardian capable of participating in informed consent process * Documented history of heavy prenatal alcohol exposure (self-report, social service records, or adoption records) or presence of facial dysmorphology characteristic of FASD or both * Evidence of cognitive deficit in at least one neurocognitive domain
Exclusion criteria
* History of neurological condition (ex. epilepsy, cerebral palsy, traumatic brain injury) * History of medical condition known to affect brain function * History of other neurodevelopmental disorder (ex. autism, down syndrome) * History of very low birthweight (\<1500 grams) * History of prenatal exposure to drugs other than alcohol, nicotine, and caffeine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Side Effects of Choline Bitartrate | Baseline, 6 months, & 9 months | Side effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact. |
| Mullen Scales of Early Learning - Early Learning Composite | Baseline and 9 months | The Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Elicited Imitation Task Memory | Baseline, 6 months, and 9 months | The Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5. |
| Evoked Response Potentials Microvolts | Baseline, 6 months, and 9 months | Evoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included. |
| Evoked Response Potential - Negative Component Latency | Baseline, 6 months, and 9 months | Evoked Response Potential - negative component latency data are included. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Choline Bitartrate Choline Bitartrate supplementation
Choline bitartrate: Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix. | 31 |
| Placebo Placebo for choline bitartrate supplementation
Placebo for choline bitartrate: Placebo for choline bitartrate, administered daily in fruit-flavored drink mix. | 29 |
| Total | 60 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Withdrawal by Subject | 5 | 3 |
Baseline characteristics
| Characteristic | Choline Bitartrate | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 3.79 years STANDARD_DEVIATION 0.8 | 3.92 years STANDARD_DEVIATION 0.76 | 3.855 years STANDARD_DEVIATION 0.78 |
| Gender Female | 19 Participants | 19 Participants | 38 Participants |
| Gender Male | 12 Participants | 10 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 15 / 31 | 13 / 29 |
| serious Total, serious adverse events | 0 / 31 | 0 / 29 |
Outcome results
Mullen Scales of Early Learning - Early Learning Composite
The Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details.
Time frame: Baseline and 9 months
Population: Including those with partial completion (drop-outs and lost-to-followup).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Choline Bitartrate | Mullen Scales of Early Learning - Early Learning Composite | 9-month follow-up | 87.1 units on a scale | Standard Deviation 16.4 |
| Choline Bitartrate | Mullen Scales of Early Learning - Early Learning Composite | Baseline | 83.2 units on a scale | Standard Deviation 13.7 |
| Placebo | Mullen Scales of Early Learning - Early Learning Composite | Baseline | 84.3 units on a scale | Standard Deviation 21.4 |
| Placebo | Mullen Scales of Early Learning - Early Learning Composite | 9-month follow-up | 89.6 units on a scale | Standard Deviation 21.6 |
Side Effects of Choline Bitartrate
Side effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact.
Time frame: Baseline, 6 months, & 9 months
Population: Children with fetal alcohol spectrum disorders receiving either choline or placebo for 9 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month cardiovascular | 1 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline respiratory problems | 6 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline musculoskeletal problems | 0 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline skin problems | 6 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month skin problems | 6 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline energy level problems | 8 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month energy level problems | 8 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 months energy level problems | 8 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline pain | 3 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month pain | 3 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month pain | 3 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month skin problems | 6 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline Ear Nose Throat problems | 1 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month Ear Nose Throat problems | 1 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month Ear Nose Throat problems | 1 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline headaches/dizziness | 2 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month headaches/dizziness | 2 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month headaches/dizziness | 2 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline vision problems | 2 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month vision problems | 0 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month vision problems | 0 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline cardiovascular | 1 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month cardiovascular | 1 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month respiratory problems | 6 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month respiratory problems | 6 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline gastrointestinal problems | 18 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month gastrointestinal problems | 18 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month gastrointestinal problems | 18 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline genitourinary problems | 4 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month genitourinary problems | 4 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month genitourinary problems | 4 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month musculoskeletal problems | 0 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month musculoskeletal problems | 0 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month neurologic/psychiatric problems | 11 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month neurologic/psychiatric problems | 11 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline neurologic/psychiatric problems | 11 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | Baseline allergic problems | 2 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 6 month allergic problems | 0 participants |
| Choline Bitartrate | Side Effects of Choline Bitartrate | 9 month allergic problems | 0 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month vision problems | 2 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month cardiovascular | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline allergic problems | 3 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month genitourinary problems | 8 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month vision problems | 2 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline musculoskeletal problems | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month genitourinary problems | 8 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline skin problems | 6 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline cardiovascular | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month neurologic/psychiatric problems | 9 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline energy level problems | 10 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month cardiovascular | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month energy level problems | 9 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline respiratory problems | 6 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 months energy level problems | 9 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month allergic problems | 3 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline pain | 4 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month respiratory problems | 6 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month pain | 4 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month musculoskeletal problems | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month pain | 4 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month skin problems | 5 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month respiratory problems | 6 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month skin problems | 5 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline neurologic/psychiatric problems | 9 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline Ear Nose Throat problems | 0 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline gastrointestinal problems | 14 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month Ear Nose Throat problems | 0 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month musculoskeletal problems | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month Ear Nose Throat problems | 1 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month gastrointestinal problems | 11 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline headaches/dizziness | 2 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month allergic problems | 3 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month headaches/dizziness | 2 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month gastrointestinal problems | 11 participants |
| Placebo | Side Effects of Choline Bitartrate | 9 month headaches/dizziness | 2 participants |
| Placebo | Side Effects of Choline Bitartrate | 6 month neurologic/psychiatric problems | 9 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline vision problems | 2 participants |
| Placebo | Side Effects of Choline Bitartrate | Baseline genitourinary problems | 9 participants |
Elicited Imitation Task Memory
The Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5.
Time frame: Baseline, 6 months, and 9 months
Population: Young choline group (n=17); Young placebo group (n=13); Old choline group (n=14); Old placebo group (n=16).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Choline Bitartrate | Elicited Imitation Task Memory | Delayed-Items-Young | 14.24 Slope | Standard Error 3.84 |
| Choline Bitartrate | Elicited Imitation Task Memory | Delayed-Items-Old | -.71 Slope | Standard Error 3.98 |
| Choline Bitartrate | Elicited Imitation Task Memory | Delayed-Pairs-Young | 18.97 Slope | Standard Error 3.65 |
| Choline Bitartrate | Elicited Imitation Task Memory | Delayed-Pairs-Old | 2.69 Slope | Standard Error 3.79 |
| Choline Bitartrate | Elicited Imitation Task Memory | Immed-Items-Young | 8.48 Slope | Standard Error 4.23 |
| Choline Bitartrate | Elicited Imitation Task Memory | Immed-Items-Old | 2.59 Slope | Standard Error 4.36 |
| Choline Bitartrate | Elicited Imitation Task Memory | Immed-Pairs-Young | 8.75 Slope | Standard Error 4.45 |
| Choline Bitartrate | Elicited Imitation Task Memory | Immed-Pairs-Old | 11.46 Slope | Standard Error 4.61 |
| Placebo | Elicited Imitation Task Memory | Immed-Pairs-Old | 5.50 Slope | Standard Error 4.46 |
| Placebo | Elicited Imitation Task Memory | Delayed-Items-Young | 4.43 Slope | Standard Error 4.04 |
| Placebo | Elicited Imitation Task Memory | Immed-Items-Young | 13.72 Slope | Standard Error 4.41 |
| Placebo | Elicited Imitation Task Memory | Delayed-Items-Old | 4.23 Slope | Standard Error 3.9 |
| Placebo | Elicited Imitation Task Memory | Immed-Pairs-Young | 20.01 Slope | Standard Error 4.8 |
| Placebo | Elicited Imitation Task Memory | Delayed-Pairs-Young | 10.39 Slope | Standard Error 4 |
| Placebo | Elicited Imitation Task Memory | Immed-Items-Old | 3.89 Slope | Standard Error 4.24 |
| Placebo | Elicited Imitation Task Memory | Delayed-Pairs-Old | 7.79 Slope | Standard Error 3.73 |
Evoked Response Potential - Negative Component Latency
Evoked Response Potential - negative component latency data are included.
Time frame: Baseline, 6 months, and 9 months
Population: Children with FASD who were administered Evoked Response Potential test and provided usable data (choline and placebo arms)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Choline Bitartrate | Evoked Response Potential - Negative Component Latency | Frontal Neg Component Latency at baseline | 2.23 Milliseconds | Standard Deviation 43.96 |
| Choline Bitartrate | Evoked Response Potential - Negative Component Latency | Frontal Neg Component at 6 months | 32.45 Milliseconds | Standard Deviation 60.31 |
| Choline Bitartrate | Evoked Response Potential - Negative Component Latency | Frontal Neg Component at 9 months | -4.00 Milliseconds | Standard Deviation 42.3 |
| Placebo | Evoked Response Potential - Negative Component Latency | Frontal Neg Component at 9 months | -3.03 Milliseconds | Standard Deviation 79.62 |
| Placebo | Evoked Response Potential - Negative Component Latency | Frontal Neg Component Latency at baseline | 5.35 Milliseconds | Standard Deviation 60.21 |
| Placebo | Evoked Response Potential - Negative Component Latency | Frontal Neg Component at 6 months | -4.28 Milliseconds | Standard Deviation 55.22 |
Evoked Response Potentials Microvolts
Evoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included.
Time frame: Baseline, 6 months, and 9 months
Population: Children with FASD who were administered Evoked Response Potential test and provided usable date (choline and placebo arms)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Choline Bitartrate | Evoked Response Potentials Microvolts | Frontal Positive Slow Wave (PSW) - 6 months | -1.04 Mircovolts | Standard Deviation 4.58 |
| Choline Bitartrate | Evoked Response Potentials Microvolts | Frontal Positive Slow Wave (PSW) - Baseline | -2.05 Mircovolts | Standard Deviation 5.49 |
| Choline Bitartrate | Evoked Response Potentials Microvolts | Frontal Positive Slow Wave (PSW) - 9 months | -0.26 Mircovolts | Standard Deviation 5.01 |
| Choline Bitartrate | Evoked Response Potentials Microvolts | Frontal Neg Component Amplitude - Baseline | -2.53 Mircovolts | Standard Deviation 5.66 |
| Choline Bitartrate | Evoked Response Potentials Microvolts | Frontal Neg Component Amplitude - 6 months | 1.22 Mircovolts | Standard Deviation 5.46 |
| Choline Bitartrate | Evoked Response Potentials Microvolts | Frontal Neg Component Amplitude - 9 months | 0.35 Mircovolts | Standard Deviation 5.53 |
| Placebo | Evoked Response Potentials Microvolts | Frontal Neg Component Amplitude - 6 months | -0.84 Mircovolts | Standard Deviation 4.94 |
| Placebo | Evoked Response Potentials Microvolts | Frontal Positive Slow Wave (PSW) - 6 months | -1.03 Mircovolts | Standard Deviation 3.48 |
| Placebo | Evoked Response Potentials Microvolts | Frontal Neg Component Amplitude - Baseline | 0.62 Mircovolts | Standard Deviation 7.56 |
| Placebo | Evoked Response Potentials Microvolts | Frontal Positive Slow Wave (PSW) - Baseline | 0.57 Mircovolts | Standard Deviation 7.24 |
| Placebo | Evoked Response Potentials Microvolts | Frontal Neg Component Amplitude - 9 months | -1.37 Mircovolts | Standard Deviation 5.08 |
| Placebo | Evoked Response Potentials Microvolts | Frontal Positive Slow Wave (PSW) - 9 months | -1.41 Mircovolts | Standard Deviation 5.23 |